Search results for "pathogen reduction"

showing 4 items of 4 documents

Platelet Pathogen Reduction Technologies Alter the MicroRNA Profile of Platelet-Derived Microparticles

2020

Despite improvements in donor screening and increasing efforts to avoid contamination and the spread of pathogens in clinical platelet concentrates (PCs), the risks of transfusion-transmitted infections remain important. Relying on an ultraviolet photo activation system, pathogen reduction technologies (PRTs), such as Intercept and Mirasol, utilize amotosalen, and riboflavin (vitamin B2), respectively, to mediate inactivation of pathogen nucleic acids. Although they are expected to increase the safety and prolong the shelf life of clinical PCs, these PRTs might affect the quality and function of platelets, as recently reported. Upon activation, platelets release microparticles (MPs), which …

0301 basic medicineAmotosalenmedicine.medical_specialtySmall RNAlcsh:Diseases of the circulatory (Cardiovascular) systemmirasolCardiovascular Medicine030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineclinical platelet concentrateInternal medicinemicroRNAmedicinePlateletHematologiPathogenOriginal ResearchRegulation of gene expressionHematologymicroRNApathogen reductionChemistryclinical platelet concentrate; pathogen reduction; mirasol; intercept; extracellular vesicles; small RNA-sequencing; microRNAHematology3. Good healthCell biologysmall RNA-sequencing030104 developmental biologylcsh:RC666-701extracellular vesiclesCardiology and Cardiovascular MedicineFunction (biology)interceptFrontiers in Cardiovascular Medicine
researchProduct


 Consistency and Proportionality in Policy Decision-Making in Blood Safety: the Case for an All-Apheresis Platelet Supply in Germany

2013

SUMMARY Recently, German investigators presented the first mathematical model finding a significant increase in the risk of HIV, HCV, and HBV transmission when pools of 4 whole-blood-derived buffy-coat platelets, rather than 1 singledonor (apheresis) component, are used to provide one platelet dose. Based, in both cases, on mathematical models employing the incidence/window-period method, the relative risk of transmission from pooled versus apheresis platelets (2.2 or 2.75 for HIV, 2.7 or 3.375 for HCV, and 3.2 or 4.0 for HBV, with pools of 4 or 5 concentrates, respectively) is similar to the difference in risk before (versus after) introduction of HIV-1 and HCV RNA screening. The absolute …

Oncologymedicine.medical_specialtybusiness.industryHuman immunodeficiency virus (HIV)Viral transmissionvirus diseasesPathogen reductionmedicine.disease_causeGeneral Biochemistry Genetics and Molecular BiologyPolicy decisionInternal medicineRelative riskImmunologymedicineBlood safetyPlateletbusinessModel findingClinical Laboratory
researchProduct

Peculiarities of studying the effects of pathogen reduction technologies on platelets.

2016

The transfusion of platelet concentrates (PCs) is mainly used for treatment of thrombocytopenic, trauma or surgery patients. The integrity and safety of these platelet preparations, however, is compromised by the presence of pathogens, such as viruses, bacteria and parasites. The transfer of allogeneic donor leukocytes contaminating PCs can also potentially cause adverse reactions in recipients. These considerations prompted the development and implementation of pathogen reduction technologies (PRT), which are based on chemically induced cross-linking and inactivation of nucleic acids. While the incumbent PRT may provide some protection against transfusion-transmitted infections, they are i…

0301 basic medicineBlood PlateletsProteomicsmedicine.medical_specialtyFuture studiesClinical BiochemistryBlood preservationfood and beveragesPathogen reductionTransfusion medicine030204 cardiovascular system & hematologyBiology03 medical and health sciencesFunctional integrity030104 developmental biology0302 clinical medicineBlood PreservationImmunologymedicineAnimalsHumansPlateletBlood TransfusionPlatelet concentrateTranscriptomeProteomics. Clinical applications
researchProduct

Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function

2014

Pathogen reduction (PR) systems for platelets, based on chemically induced cross-linking and inactivation of nucleic acids, potentially prevent transfusion transmission of infectious agents, but can increase clinically significant bleeding in some clinical studies. Here, we documented the effects of PR systems on microRNA and mRNA levels of platelets stored in the blood bank, and assessed their impact on platelet activation and function. Unlike platelets subjected to gamma irradiation or stored in additive solution, platelets treated with Intercept (amotosalen + ultraviolet-A [UVA] light) exhibited significantly reduced levels of 6 of the 11 microRNAs, and 2 of the 3 anti-apoptotic mRNAs (B…

AmotosalenBlood Plateletstransfusion medicineplatelet functionbcl-X ProteinEndogenyPharmacologyHumansPlateletPlatelet activationRNA MessengerMean platelet volumeplateletClusterinbiologypathogen reductionGene Expression ProfilingImpaired platelet aggregationRNAMicroRNAHematologyGeneral MedicinePlatelet ActivationMolecular biologyMicroRNAsClusterinBlood Preservationbiology.proteinOriginal ArticleTranscriptomeMean Platelet VolumePlatelets
researchProduct